All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2026-05-01.
From the record
Atara Biotherapeutics, Inc.'s filings since 2017 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-05-01) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+23.8% a year over 4 filed years; profitable in 1 of 4.
From the record
Atara Biotherapeutics, Inc.'s 4 filed years say what it did: revenue went from $64 million in fiscal 2022 to $121 million in fiscal 2025, up 23.8% a year; it rose in 1 of 3 years; the deepest fall was 87% from fiscal 2022 to fiscal 2023; net income was positive in 1 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.0/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Atara Biotherapeutics, Inc.'s shareholder treatment is put at 3.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 30% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 290%: owes 290¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Atara Biotherapeutics, Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 290 cents per dollar of assets, and net share issuance: its share count grew 69.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 23% of 102 in its family; net margin 27.1%.
From the record
Atara Biotherapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $121 million in fiscal 2025 ranks in the top 26% by size; a net margin of 27.1% ranks in the top 11%; revenue growth of 23.8% a year over the last 3 filed years ranks in the top 30% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 10% of 110 in its family for leadership; chief executive since 2024.
From the record
Atara Biotherapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Nguyen, Anhco (President and CEO, as filed), filing under that title since 2024-09-11, 2.2 years (bottom 25% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 1.6 years (bottom 1%); 12 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 4%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 50% of 92 in its family for room to expand.
From the record
Atara Biotherapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $8 million against no long-term debt tagged leaves 41.9% of its assets as net cash, top 39% of its family; cash from operations less capital spending is -42.2% of revenue (top 31%); research spending of 31% of revenue (bottom 20%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 32% of 100 in its family for growth drivers.
From the record
Atara Biotherapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 23.8% a year over the last three filed years against 23.8% over all 4, speeding up (top 36% of its family); the newest year grew -6.3% (bottom 30%); research spending grew -48.4% a year (bottom 2%) (its annual reports). Atara Biotherapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 36% of 72 in its family for expectations against reality.
From the record
Atara Biotherapeutics, Inc.'s newest year against its own record: revenue of $121 million in fiscal 2025 came in 34.2% below the $184 million its prior three years' pace pointed to (bottom 22% of its family); net income of $33 million against a prior three-year average of $197 million (top 13%); a net margin of 27.1% against losses larger than its revenue before (top 17%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made